한미약품

128940KOSPI의약품 제조업

52.5 / 100

Reference Date: 2026-04-13

Financial Score17.5 / 40

News Sentiment13.0 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanmi Pharmaceuticals operates in three segments: pharmaceuticals, APIs, and overseas pharmaceuticals. It produces and sells key drugs such as the hypertension treatment 'Amozaltan' and has a global presence through its API division, Hanmi Precision Chemicals, which holds international certifications like FDA. Its overseas subsidiary, Beijing Hanmi, focuses on pediatric medications and hypertension treatments in the Chinese market.

Number of Employees

2,382people

Average Salary

86.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

37.39Industry Average 14.800.0Point

2.5x industry avg (risky)

PBR

4.50Industry Average 1.040.0Point

4.3x industry avg (risky)

ROE

14.05Industry Average 4.427.0Point

3.2x industry avg (excellent)

Debt Ratio

7.70Industry Average 11.985.0Point

Lower than industry avg (good)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 13.9% (declining, 3yr)

Detailed News Sentiment

55 totalPositive 5Neutral 44Negative 1Average Sentiment Score 52.2

Detailed Momentum

52-week position6.0Point

52w upper range (67%)

Current 500,000Won52-week high 626,00052-week low 234,500

1-month return3.0Point

1m 0.7% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

12 totalPositive 0Neutral 12Negative 0

Neutral최대주주등소유주식변동신고서2026-04-07
Neutral주식등의대량보유상황보고서(일반)2026-04-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01
Neutral정기주주총회결과2026-03-31